Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
UNIVERSITE DE MONTPELLIER is managing 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is decentralized, with 7 distinct examiners assigned to the active matters. This distribution extends to the organizational level, as the cases are spread across 7 distinct art units. POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner currently associated with the portfolio, overseeing 1 busiest examiner pending action.
The presence of 7 pending office actions suggests that the company's intellectual property is being evaluated across multiple USPTO divisions. Because the workload involves 7 distinct examiners, the applicant must navigate various prosecution styles within the Biotechnology & Pharmaceuticals sector. POLIAKOVA-GEORGAN, EKATERINA handles 1 busiest examiner pending action, meaning the workload is not concentrated under a single individual. The use of 7 distinct art units indicates that the pending applications cover a broad range of technical specialties, requiring a diverse legal strategy to address the requirements of each assigned unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| LAFAVE, ELIZABETH ROSE | 1 | 62.5% | +45.4% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 15d |
| 18278494 | ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | DEKARSKE, MADELINE MCGUIRE | — |
| 18248240 | NOVEL PEPTOIDS AND USE THEREOF FOR PREVENTING OR TREATING CHRONIC PAIN | NIEBAUER, RONALD T | — |
| 17918468 | PROGNOSIS METHOD OF ACUTE MYELOID LEUKAEMIA | MYERS, CARLA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275331 | BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSITC AND THERAPEUTIC PURPOSES | ARMATO JR, DENNIS IGNATIUS | 30d overdue |
| 18041902 | EUKARYOTIC DNA REPLICATION ORIGINS, AND VECTOR CONTAINING THE SAME | LAFAVE, ELIZABETH ROSE | 6d |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 15d |
| 18278494 | ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18248240 | NOVEL PEPTOIDS AND USE THEREOF FOR PREVENTING OR TREATING CHRONIC PAIN | NIEBAUER, RONALD T | — |
| 17918468 | PROGNOSIS METHOD OF ACUTE MYELOID LEUKAEMIA | MYERS, CARLA J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1622 | 1 |
| 1651 | 1 |
| 1658 | 1 |
| 1684 | 1 |
| 1682 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278494 | ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §101§103 | Final Rejection | — | Pending | Aug 23, 2023 |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18275331 | BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSITC AND THERAPEUTIC PURPOSES | ARMATO JR, DENNIS IGNATIUS | 1651 | §103 | Final Rejection | 30d overdue | Pending | Aug 01, 2023 |
| 18248240 | NOVEL PEPTOIDS AND USE THEREOF FOR PREVENTING OR TREATING CHRONIC PAIN | NIEBAUER, RONALD T | 1658 | §103§112 | Final Rejection | — | Pending | Apr 06, 2023 |
| 18041902 | EUKARYOTIC DNA REPLICATION ORIGINS, AND VECTOR CONTAINING THE SAME | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Non-Final OA | 6d | Pending | Feb 16, 2023 |
| 17918468 | PROGNOSIS METHOD OF ACUTE MYELOID LEUKAEMIA | MYERS, CARLA J | 1682 | §101§112 | Non-Final OA | — | Pending | Oct 12, 2022 |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 1634 | §102§103 | Non-Final OA | 15d | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial